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SUMMARY.-Eighty patients with advanced metastatic renal cancer have been
treated with hormones, chiefly medroxyprogesterone acetate (Provera). This
progestational compound is remarkably free from side-effects and can be given
in high dosage for long periods without serious complications. Ninety per cent
of cases had multiple metastases: in 76% more than one organ was involved
and nearly 50% were seriously ill or " terminal ".
Subjective improvement occurred in at least 55%. In 11 patients there was
marked improvement in the radiological or clinical signs of tumour within
2 to 6 weeks of commencing treatment or changing to a different hormone.
In two further cases improved general health was associated with stationary
metastases for 20 months. A significant objective response occurred in 16%
of the total series. A favourable response was seen more often in men (21%)
than in women (8%). If deaths within 6 weeks are excluded the objective
response rate in men is increased to 27%. Although the response of advanced
renal cancer to hormonal treatment is usually incomplete and of brief duration,
it is possible for such treatment to offer a " new lease of life " to a seriously ill
patient, even in old age, for 2 to 3 years.
BETWEEN 75% and 80% of patients treated for renal cell carcinoma will die
within 10 years of their primary treatment, the majority with distant metastases.
In a few of these cases the natural history of the disease will be unusual. For
example, growth of metastases may be exceptionally slow or, following removal
of a solitary lesion, the patient may live for a number of years without further
recurrence. Very rarely spontaneous regression ofpulmonary deposits may occur.
For the vast majority of cases, however, the onset of clinical metastases heralds
death within a year or two.
The treatment of advanced renal cancer with cytotoxic drugs has been disap-
pointing. Woodruff et al. (1967) reviewed the literature on this subject, and of
243 collected cases treated with 33 different non-hormonal agents only 10%
showed signs of objective improvement: in most instances this was slight or of
brief duration. Talley et al. (1969) have published their personal experience
with various cytotoxic drugs against metastatic hypernephroma. Of 57 patients
treated with 15 different non-hormonal compounds, chiefly alkylating agents,
antimetabolites and vinblastine, objective improvement was seen in only two
cases (3.50%). Apart from these poor results, the agents employed are highly
toxic and have a relatively small margin of safety.
* Based on a pa.per read at the Upjohn Symposium on
" Provera in Treatment of Some
Malignancies ", The Royal Society of Medicine, October 27, 1970.PROVERA TREATMENT OF METASTATIC RENAL CANCER
In previous publications we have drawn attention to clinical, pathological and
experimental evidence in support of the concept of a hormonal background to
carcinoma of the kidney, and to the possibility of achieving worthwhile palliation
in a small proportion of very advanced cases by the administration of gonadal
hormones, chiefly progestins (Bloom et al., 1963a 1963b; Bloom and Wallace,
1964; Bloom, 1964, 1967). Such agents appear to be not only more successful
in controlling the disease than cytotoxic drugs, but are also remarkably free
from serious side-effects following prolonged administration in large doses.
A transplantable renal adenocarcinoma of the golden hamster, induced by
prolonged oestrogen administration (Matthews et al., 1947; Kirkman, 1959;
Horning, 1956), has been employed as an experimental model with which to try
and find hormonal agents which may be of value in the treatment of advanced
renal cancer in man (Bloom et al., 1963a, 1967).
Primary tumour induction in the hamster by oestrogen can be inhibited by the
simultaneous administration of testosterone or progesterone (Kirkman, 1959;
Horning, 1956). Provera combined with cortisone, but not alone, markedly
reduced the growth rate of " independent " tumour transplants (Bloom et al.,
1963a). Actual tumour regression was achieved by orchiectomy and this action
was nullified by the administration of oestradiol (Bloom et al., 1963b). For this
reason the effect of anti-oestrogens.was investigated and the first of these studied,
U-l lOOA (Upjohn Ltd.), a diphenyldihydronaphthaline derivative, had a marked
inhibitory effect on the transplantable tumour (Bloom et al., 1967). Other agents,
including those with known anti-oestrogenic properties, are under investigation
in our laboratories at the present time.
Caution is necessary when trying to extrapolate from observations in laboratory
animals to clinical practice, but because the principal actions of hormonal agents
are fundamentally alike in most species, it is tempting to apply knowledge derived
from endocrine-dependent tumours in animals to possibly analogous tumours in
man. Although the kidney is not generally regarded as a member ofthe endocrine
system, a direct link between hormones and human renal cancer exists in the rare
but well-recognised association of renal cell carcinoma with polycythaemia and
with hypercalcoemia due to the " ectopic " secretion of erythropoietin and para-
thormone, respectively, by the tumour.
The male predominance found in renal cortical carcinoma series and in cases of
spontaneous regression of this tumour, the effect of sex hormones on the normal
kidney in experimental animals, and the induction and inhibition of the hamster
renal tumour by such agents, encouraged us in 1959 to embark on a clinical trial
of gonadal hormones, chiefly the progestin, provera, in patients with advanced
renal cancer (Bloom, 1964).
PATIENTS AND METHODS
Between 1959 and 1969 80 patients with incurable renal adenocarcinoma have
been treated with hormonal agents. Only cases with clear evidence of advancing
disease for whom no other treatment, except by cytotoxic drugs, was feasible were
accepted for hormone therapy. In this category no case was refused treatment,
no matter how near death they appeared to be. Thus, 20 very ill patients died
within 6 weeks of commencing hormone treatment (25% of the total).
The series consisted of 54 men and 26 women. A nephrectomy had been
carried out in 67 patients and histological confirmation of the diagnosis of renal
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carcinoma was obtained in 73 (91%). Of the 80 cases 94% had multiple meta-
stases and in 76% more than one organ was known to be involved (Table I).
Thirty-eight cases (47%) were seriously ill or considered to be " terminal"
when hormone therapy was instituted. In 19 cases (24%), the liver was enlarged,
in eight as far asthe umbilicus. Sevenpatients had cerebral metastases. Skeletal
deposits were present in 23 (29%) cases, and pulmonary or mediastinal lesions
in 57 (71%). A laparotomy in seven patients revealed that proper removal of
the primary tumour was impossible (Table I).
TABLE I.-Cases ofAdvanced Renal Adenocarcinoma Treated with
Hormones. 80 Cases (1959-69)
Site Cases %
Multiple metastases . . . 75 . 94
Multiple different organs involved . 61 . 76
Lungs, mediastinum . . . 57 . 71
Skeleton . . . . . 23 . 29
Hepatomegaly* . . . . 19 24
Brain . . . . . . 7 . 9
Inoperable primaryt . . . 10 12
Other abdominal massest . . . 17 . 21
Seriously ill or terminal . . . 38 . 47
Presented primary + metastases . 32 . 40
* Umbilical level in 8; t Laparotomy in 7; 1 > 12 cm. in 9.
Treatment in all cases was initiated with progestins-Provera in 79 cases and
Delalutin in one case. Provera or medroxypyrogesterone acetate (6a-methyl,
17a-acetoxy-progesterone) is a powerful progestational agent synthesized in the
laboratories of Upjohn Ltd (Babock et al., 1958) which is devoid of oestrogenic
and androgenic properties. It may be given orally or as a suspension intra-
muscularly. Prolongedadministration topatients even inhigh doses (300-400 mg.
daily) appears to be virtually free from serious toxic effects. In the present
series the oral preparation ofProvera was used 100 mg. t.i.d. Delalutin or Primo-
lut Depot (Schering) (hydroxyprogesterone caproate) was given in a dose of
250 mg. i.m. thrice weekly.
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RESULTS
Ofthe 80 cases 78 have been followed until death; one foreign patient remains
untraced and one case is still alive. A significant degree of subjective improve-
ment was experienced by 44 patients (55%) following the administration of one
or more hormone preparations. Attention will be given only to cases withPROVERA TREATMENT OF METASTATIC RENAL CANCER 253
objective signs of tumour regression or where the tumour remained stationary for
more than 1 year. In this category ten cases thought to show some response
have been mentioned but excluded from the final consideration because the
change was of a very limited nature, lasted for 1 month or less, or was not con-
firmed by the present author.
Eleven cases (14%) remain inwhich undeniable improvement in theradiological
or clinical signs of tumour occurred within a short time of commencing treatment
or changing to a different hormone and lasted for 2-35 months (Tables II and
III). There were two additional cases in whom marked improvement in general
condition was associated with stationary tumour for 20 and 21 months respectively
(Table IV). Histological confirmation of the diagnosis was obtained in all 13
cases, and in five of the 11 dead cases an autopsy was performed.
TABLE II.-Advanced Renal Adenocarcinoma. Results of
Hormone Treatment. 80 Cases
Response Cases %
Subjective . . . . 44 . 55
Objective
Marked tumour regression . . 11* . 14
Tumour stationary > 1 year . 2t 25
Slight tumour regression . . 10 . 12
Total objective . . 23 . 29
* For 2, 2, 3, 3, 3, 9, 13, 20, 24, 24, 35 months.
t For 21, 20+ months.
TABLE II.-Hormone Therapyfor Metastatic Renal Cancer Marked Objective
Response
The organs in which tumour regression occurred are underlined. In some patients not all
known tumour sites responded to treatment.
Duration Survival
of from start
Sex Extent prior to Successful response ofhormones
Case age hormones hormone (months) (months)
A.P. . & 70 . Lung, bone . Provera . 20 . 32
D.W. . < 58 . Lung, bone, brain . Testosterone . 35 . 41
G.D. . <364 . Lung . Provera . 9 13
W.D. . & 59 . Liver, lung, inop. . Provera 3 3
primary
A.J. . $ 69 . Abdominal masses . Provera . 3 . 7
F.H. . < 49 Abdomen, * fDelalutin 22 24
suprac. nodes Testosterone . J
J.A.D. . d 78 Lung, scar . Provera 24 . 37
B.S. . Y 58 . Inop. primary, liver Provera . 2 . 3
A.G. . 3 82 . Scar, abdomen Provera . 3 14
E.G. . & 58 . Lungs, abdomen P rProvera . 9 20 Testosterone . 4 20
Y.A. . & 65 . Scar, abdomen Provera . 2-5 Untraced
The overall significant objective response rate is 16% (13 of 80 cases). If the
20 seriously ill patients who died within 6 weeks of starting hormone therapy
are excluded on the grounds of insufficient time for a chemotherapeutic effect, a
practice endorsed by several authors, the response rate is 22% (Table VI).H. J. G. BLOOM
TABLE IV.-Disease Stationaryfor >12 Months
Sex Extent prior to
Case age hormones Hormone Response Survival
A.D. . 71 . Bone, lung . Provera . Multiple bone mets. . Died
stationary 21 months . 22 months:
Testosterone . Regressionlung mets. . lung and
15 months spinal mets.
active.
W.G. . 62 . Mediastinum . Provera . Mass stationary 20+ Alive and
months well 20
months
ILLUSTRATIVE CASE SUMMARIES
Partial Selective Regression
Case A.P., male aged 70 (Bloom, 1964)
Metastases in left lung and lower femur 4 years after nephrectomy. Oral Provera, 300 mg.
daily, prescribed and irradiation to femoral deposit because of pain and risk of fracture.
Six weeks later large lung deposit smaller but femoral lesion advancing. By 4 months mid-
thigh amputation for pathological fracture. Pulmonary metastasis continued to regress and
finally became stationary: this response maintained for 20 months. Progressive destruction
of femoral stump required hip disarticulation. Intrathoracic metastases recurred with no
response to larger doses of Provera nor to prednisone, Provera plus prednisone and finally
testosterone. Death with wide-spread metastases 32 months after starting hormone therapy.
R6s8UM.-Partial regression of large pulmonary metastasis commencing within 5 weeks
and lasting 20 months: no response of skeletal deposit which advanced during treatment.
Case B.S., female aged 58 (Bloom, 1967)
General condition very poor, massive tumour in solitary kidney and hard irregular liver
to umbilicus. Nephrectomy for tuberculosis 32 years previously. Recent excision of
thyroid mass which showed metastatic clear cell adenocarcinoma. Nephrotomogram
revealed small cap of functioning renal tissue atop a large renal tumour. Oral Provera
300 mg. daily started. After 10 days improved general condition, increased appetite, weight
gain, morephysical activitywithless fatigue andrenal mass smaller: hepatomegalyunchanged.
Discharged from hospital after 6 weeks with renal tumour approximately one-third of its
original size, but liver unchanged. General improvement and response of primary tumour
maintained for 2 months after which there was deterioration and increasing hepatomegaly.
No response to testosterone. Death 3 months after commencing hormone therapy. Autopsy:
large renal tumour showing extensive areas ofnecrosis and calcification. Histology: residual
clear cell adenocarcinoma and extensive areas of anaplastic tumour with marked pleomor-
phism and hyperchromatism.
Re'sume.-Rapid partial regression of massive primary tumour. Unchanged metastatic
liver. Was the partial response limited to the areas ofmore differentiated tumour?
Total Selective Regression
Case G.D., male aged 64 (Bloom, 1964)
Presented with renal tumour and solitary pulmonary shadow. Pre-operative irradiation
for primary tumour during which time pulmonary deposit increased. Nephrectomy carried
out. Two months later chest X-ray showed numerous bilateral lung lesions. Oral Provera,
300 mg. daily, started. Five weeks later pulmonary deposits reduced in size and number,
and after 2 months all but two lesions had disappeared. These remained stationary for
8 months during which time patient was symptom-free and travelled abroad. Metastases
then advanced with no response to prednisone or testosterone. Urinary complications
developed suggesting metastases in remaining kidney. Died at home 13 months after
starting hormone therapy.
Resume.-Disappearance of all but two metastases in lung within 8 weeks. Response
lasted 9 months.
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Case W.D., male aged 59 (Bloom, 1964)
Huge inoperable renal tumour and bilateral pulmonary metastases. During pre-operative
irradiation to primary tumour, pulmonary lesions increased. At laparotomy (Sir Eric
Riches) large fixed kidney tumour with deposits in liver, para-aortic nodes and diaphragm.
Biopsy of diaphragmatic nodule confirmed renal cell carcinoma. Post-operatively, general
condition deteriorated further and pulmonary deposits and abdominal swelling increased.
Oral Provera, 300 mg. daily, started. Six days later patient felt and looked rather better.
By 13 days definiteimprovement in appearance and some regression ofpulmonary metastases.
Discharged home 15days after starting hormonetherapy. At 8 weekslung clearbut abdomen
still distended by large liver and ascites. Death at home 3 months after starting
Provera.
Re8umre.-Clinical improvement within 1 week; objective response within 2 weeks.
Complete disappearance of pulmonary metastases within 8 weeks but no change in hepato-
megaly.
Total Regression
Ca8e J.A.D., male aged 78
General weakness, chest and abdominal symptoms 9 months after nephrectomy. Abdo-
minal mass 15 x 12 cm. involving nephrectomy scar (Fig. la): second more superficial
mass 8 x 6 cm. in drain scar (Fig. lb). Multiple small bilateral lung metastases (Fig. 2a).
Marked subjective and objective response within 2 weeks ofcommencing oral Provera 300 mg.
daily. By 4 weeks larger abdominal tumour reduced to 6 x 6 cm. and smaller to 2*5 cm.
At 8 weeks chest clear (Fig. 2b) and total regression ofsmaller abdominal recurrence. Larger
abdominal tumour now a superficial lump 3-5 cm. (Fig. 1c). General condition good;
symptom-free; able to walk 2 miles daily.
At 3 months excision ofresidual abdominal tumour 2-5 cm. (Fig. 3). Histology: secondary
renal cell carcinoma (Fig. 4a), appearance suggesting lower grade activity than original
primary (Fig. 4b).
Patient passed 80th birthday in good health (Fig. 5b). Abdominal recurrence 25 months
after starting Provera which progressed slowly over 12 months during successive admini-
stration of larger doses of Provera (400 mg. daily), an anti-oestrogen (Ul-lIOOA) and testo-
sterone. Death aged 81, 3 years after commencing hormone therapy.
R&sume.-Rapid total disappearance of lung metastases and scar recurrence. Sub-total
regression of huge abdominal tumour. Benefit lasted 2 years.
Tumour Acceleration with Provera: Total Regresion with Testosterone
Case D.W., male aged 58 (Bloom and Wallace, 1964)
Presented with renal tumour and metastases in tibia, chest, and skull. Nephrectomy
(D. M. Wallace). Because of pain and risk of fracture large osteolytic deposit upper tibia
treated by irradiation, curretage, bone-chip replacement and insertion of intramedullary nail
(G. R. Fisk). Whilst receiving oral Provera 300 mg. daily over 2 months marked general
deterioration, onset of hemiparesis and increase of intrathoracic and unirradiated skeletal
metastases. Provera replaced by 100 mg. testosterone i.m. daily, 5 days weekly. Within
4 weeks striking improvement in general health; by 8 weeks described as a " new man
After 18 months on testosterone patient was in good health and full employment: weight
gain 23 kg., recovery from hemiparesis. Radiological regression of metastases in skull and
tibia (unirradiated area). Surgically treated and irradiated tibial metastasis healed. Chest
clear. Continued in good health with no evidence of active disease for 3 years. Then
sudden collapse with hemiplegia. No recurrence of skeletal lesions but new soft tissue
metastases. Stilboestrol, prednisone and further testosterone all tried in turn without effect.
Death with visceral metastases 41 months after starting hormone therapy. At autopsy,
previous large skull defect covered by fibrous membrane with no evidence ofresidual tumour.
(Full illustrated account ofthis case in British MedicalJournal, August 22, 1964, pp. 476-480).
R68ume.-Tumour acceleration with Provera. Rapid improvement on changing to
testosterone. Total regression of chest and skeletal metastases for 35 months.
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Partial Selective Regression with Two Separate Hormones
Case E.G., male aged 58
Pulmonary deposit and abdominal mass with scar involvement 6 years after nephrectomy.
Gradual increase of pulmonary lesion over 12 months whilst abdominal mass remained
quiescent following local irradiation (4000 R). Returned with painful abdominal tumour
9 x 10 cm. and large lung mass. Oral Provera 300 mg. daily started. Within 3 weeks
pain-free and reduction of abdominal mass to 7 x 7 cm. At 6 weeks, improved general
condition and weight gain 2-5 kg. By 12 weeks abdominal tumour stationary at 5 x 5cm.:
lung deposit unchanged throughout. This situation continued for 10 months from onset of
Provera. Then abdominal tumour increased to 14 x 13 cm. within 8 weeks. Provera
replaced by testosterone, initially 100 mg. i.m. daily, 5 days weekly. Second subjective and
objective response, abdominal tumour shrinking to 8 x 8 cm. within 4 weeks. General
condition remained excellent, lung deposit unchanged, and abdominal mass stationary at
4 x 4 cm. After 4 months chest lesion advanced producing mediastinal obstruction which
was treated by irradiation. Abdominal tumour still stationary. General deterioration with
death at home, 20 months after commencing hormones.
Re8sum.-Rapid subjective improvement and partial regression of abdominal tumour,
first with Provera and later with testosterone. No change in pulmonary mass with either
agent.
Tumour " Stand-still"
Case W.G., male aged 62
Renal tumour and superior mediastinal mass. Nephrectomy; tumour invading posterior
abdominal wall and para-aortic region. General weakness, poor appetite and weight loss.
Oral Provera 300 mg. daily started because of known residual disease in abdomen and the
mediastinal tumour, presumed lymph node metastases. Within 15 days felt better, appetite
improved and weight increased by 2-25 kg. At 12 months general condition good, total
weight gain 13-5 kg. Alive and well 20 months after commencing Provera: mediastinal
mass completely unchanged; no new lesions.
R8sumJ.-Improved general condition, stationary mediastinal mass and no recurrence
of known post-operative residual abdominal disease at 20 months.
Case A.D., male, aged 67
Widespread skeletal metastases involving cervical and dorsal spine, skull, humeri, pelvis
and femora 4 years after nephrectomy. Also two deposits in left lung. Oral Provera 300 mg.
daily started, but because of risk of quadriplegia due to collapse of C4, cervical spine irradi-
ated. Marked general improvement with weight gain. After 3 months lungs practically
clear. Radiological evidence of healing in cervical spine (irradiated). All other osteolytic
skeletal deposits unchanged. At 15 months recurrence of disease in left lung but general
EXPLANATION OF PLATES
FIG. la.-Case J.A.D. Large abdominal recurrence (15 x 12 cm.) 9 months after nephrec-
tomy for renal carcinoma.
FIG. lb.-Case J.A.D. Drainage scar recurrence 8 x 6 cm.
FIG. lc.-Case J.A.D. Regression of abdominal tumour to 3-5 cm. and disappearance of
drainage recurrence 8 weeks after starting oral Provera 300 mg. daily.
FIG. 2a.-Case J.A.D. Multiple bilateral pulmonary metastases.
FIG. 2b.-Case J.A.D. Disappearance of all pulmonary metastases after 8 weeks treatment
with Provera.
FIG. 3.-Residual abdominal tumour 2 -5 cm. excised after 12 weeks treatment with Provera.
FIG. 4a.-Histology of residual tumour seen in Fig. 3 ( x 300). Renal carcinoma deposit
appearing less active (lower grade) than original primary tumour in Fig. 4b.
FIG. 4b.-Renal cell carcinoma-nephrectomy specimen ( x 300).
FIG. 5a.-Patient J.A.D. one month after commencing oral Provera for extensive pulmonary
and abdominal recurrent renal carcinoma.
FIG. 5b.-Case J.A.D. Aged 80, clinically and radiologically still free from disease after
receiving Provera for 15 months. Excellent response maintained for 2 years.
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condition good and skeletal lesions stationary. Provera replaced by testosterone (100 mg.
i.m. daily 5 days/week): no improvement in chest; skeletal deposits unchanged. Hormone
therapy abandoned after 20 months and 5-fluouracil tried. Within 6 weeks of stopping
hormones metastases in dorsal spine produced sudden paraplegia. Death 22 months after
commencing hormone therapy.
Re8ume.-Subjective improvement and regression ofpulmonary metastases for 15 months.
All skeletal metastases stationary for 21 months. Spinal cord compression 6 weeks after
abandoning hormone therapy.
INTERVAL TO HORMONE RESPONSE
The interval between commencing or changing a hormone preparation and
signs of clinical improvement in the 11 cases showing tumour regression has been
remarkably short-between 2 and 6 weeks (Table V). Patients may feel and
TABLE V.-Renal Adenocarcinoma Hormone-Response Interval
All cases responding to endocrine therapy had evidence of subjective and objective
improvement within 6 weeks of commencing or changing the hormonal agent.
Response interval
A
Subjective Objective
Case Hormone (weeks) (weeks)
A.P. 6' 70 . Provera . 5 5
D.W. 6' 58 . Testosterone . 4 6
G.D. 6' 64 . Provera . 5 5
W.D. d 59 . Provera . 1 2
A.J. $ 69 . Provera . 2 2
F.H. 6' 49 . Delalutin . 4 4
J.A.D. 6' 78 Provera . 2 2
B.S. ? 58 . Provera . 2 2
A.G. 6' 82 . Provera . 2 2
E.G. 6' 58 .Provera 3. E8Testosterone 4 4
Y.A. 6' 65 . Provera . 2 2
look better within a week or 10 days. In six cases evidence of tumour regression
was seen within 2 weeks. From this experience it seems that if a hormone
preparation fails to improve a patient with renal cancer it is unnecessary to delay
the trial of an alternative preparation beyond 6 to 8 weeks. It is interesting to
note that progestin-induced histological changes in cases of endometrial cancer
were observed within only 4 weeks in 75% of responding cases: in the remaining
25% such changes were delayed for 8-12 weeks (Sherman, 1966). On the other
hand, experience elsewhere with renal cancer has indicated that signs of improve-
ment may not appear until 2 months after starting hormone therapy (Samuels
et al., 1968; Paine et al., 1970). Talley and his colleagues (1969) had to wait as
long as 5 and 8 months before observing regression in their two cases. Our current
policy is not to interrupt the initial hormone treatment so long as the patient's
general condition is satisfactory and the recurrent or metastatic disease remains
stationary.
DIJRATION OF LIFE IN HORMONE-TREATED CASES
In the present series the average duration of life from onset of hormone treat-
ment in 78 of the 80 cases was 7-2 months. Of the remaining two cases one isH. J. G. BLOOM
still alive at 20 months and the other is untraced. This average figure is compar-
able to that reported by Royce and Tormey (1955) for non-hormone treated cases
presenting pre-operatively with metastases (6-7 months), and to that for patients
with local tumour extension outside the kidney at operation (5.7 months). The
average survival for 67 non-responding hormone-treated cases in the present
series was 5 2 months, whereas that for 11 patients (13 less one untraced and one
still alive) showing a well-marked objective response to hormone therapy was
substantially longer-19.6 months. Compared with advanced cases not treated
with hormones this is a conservative figure, since the duration oflife in the present
series had been measured from the onset of hormone therapy which in many
patients was introduced some time after the appearance ofrecurrent tumour. It
appears that an objective response of renal carcinoma to hormone therapy is
accompanied by prolongation of life, a conclusion also reached by Samuels et al.
(1968).
FACTORS RELATED TO HORMONE-RESPONSE
Sex
Reference has already been made to the influence of sex on the development
of renal tumours in hamsters and on the incidence of carcinoma of the human
kidney (Bloom, 1964). In the present series marked objective improvement
following hormone therapy was seen more often in men (11 of 54 cases, 20%)
than in women (two of 26 cases, 8%). Furthermore, the response in each of the
two female cases was of a very limited nature. The best results in the present
series, including the total disappearance oflarge metastatic or recurrent tumours,
have been confined to men. On the other hand, Samuels et al. (1968) refer to a
woman aged 56 with complete regression of an abdominal recurrence during
treatment with Provera and in whom the response was still maintained at 30
months.
Ifthe 20extremely ill patients who diedwithin 6 weeks ofcommencing hormone
therapy are excluded, the proportion of cases showing a marked response to this
treatment is increased to 27% for men, compared with 10% for women (Table
VI).
TABLE VI.-Advanced Renal Adenocarcinoma Response to
Hormones. Excluding 20 Cases Dying < 6 Weeks
Sex Cases Marked tumour inhibition
C . 41 . 11 (27%)
S? . 19 2 (10%)
Total . 60 . 13 (22%)
Age
The mean age of the 13 patients showing a well-marked objective response
to hormone treatment was greater by a decade than for hormone-resistant cases
(64.6 compared with 54-3 years). Complete tumour regression may occur even
in old age; one of the most impressive responses occurred in a man aged 78 (case
J.A.D.) and lasted 2 years.
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"Tumour-free interval "
This represents the time between nephrectomy and the appearance of meta-
stases. For patients with inoperable primary tumours this period has been taken
from the date of laparotomy or radiological diagnosis. For those presenting
with both metastases and a primary tumour the interval is regarded as " zero ".
The mean free-interval for the 13 cases showing a definite objective improvement
during hormone treatment was 21F5 months, compared with 101 months for
57 cases showing no such response, and 15-2 months for nine cases showing a
slight response. Although this suggests that the hormone-dependent tumours
were of a lower biological potential than the resistant lesions, no less than six of
the 13 cases showing a marked hormone response had distant metastases when
they first attended hospital.
TUMOUR ACCELERATION DURING HORMONE TREATMENT
It is well known that tumour growth rate in men with prostatic cancer may be
increased by the administration of testosterone, and in pre-menopausal women
with breast cancer by oestrogen.
Apparent tumour acceleration during hormone treatment of renal cancer
occurred in five cases in the present series. In two ofthese, however, the increase
in tumour size was probably related to an inflammatory reaction, perhaps associ-
ated with acute necrosis, since the swelling subsided spontaneously within a few
hours ordays whilstthepatient continued onthe samehormone. Intheremaining
three cases the changes were progressive and associated with deterioration in
general health: this was so rapid in one case as to demand emergency admission
to hospital within 48 hours of commencing hormone treatment. Acceleration of
tumour growth with serious consequences during hormone therapy occurred in
three of our 80 cases, an incidence of 4%. The hormone in two patients was
Provera and in the third, testosterone. Clinical improvement in all three patients
occurred with a change in hormone preparation.
In one patient skeletal and intrathoracic metastases increased rapidly during
Provera treatment: manifestations of intracranial metastases appeared and the
patient's general condition quickly deteriorated. When testosterone was substi-
tuted for the progestin, the patient improved quite dramatically, returning
rapidly to good health without evidence of active disease for 3 years (Case D.W.)
(Bloom and Wallace, 1964). Although tumour stimulation by hormones was not
observed in experiments with the strain oftransplanted hamster renal carcinoma
used in our laboratories (Bloom et al., 1963a), an increase in tumour growth rate
was reported by Kirkman (1959) when testosterone was administered to
stilboestrol-treated animals bearing the transplanted " oestrogen-dependent"
strain of tumour.
The possible stimulation of renal cancer during hormone treatment must be
borne in mind, and patients should be seen at short intervals in the early stages of
such treatment. For this reason we have waited for clear evidence of advancing
disease before embarking on endocrine therapy. Renal cancer metastases may
occasionally remain latent for a time, or progress only very slowly, and in such
patients no treatment at all may be preferable to a regime which may disturb a
satisfactory tumour-host relationship. This concept is particularly important if
hormone administration is ever considered in a prophylactic role as part of the
curative treatment of primary renal carcinoma.
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REPORTS IN THE LITERATURE
Six reports from other centres concerning the treatment of advanced renal
cancer with hormones are shown in Table VII. Apart from the groups reported
by Jenkin (1967) and by Talley et al. (1969) the overall picture is that of one in
five or six cases responding to this treatment. An objective response was seen
in 16% of the total of 173 collected cases, including those in the present series
(Table VII).
TABLE VII.-Advanced Renal Adenocarcinoma Treated with
Progestins/Testosterone. Collected Results
Successful hormone
Objective
Author Cases response P T
Woodruff et al. (1967) . 4 . 1 (25%) . 1
Melander et al. (1967) 20 4 (20%) * P + T 4
Jenkin (1967) . . 15 . 1 (7%) . 1
Samuels et al. (1968) . 23 . 4 (17%) . 3 1
Talley et al. (1969) . 16 . 2 (12%) * 2 0
Paine et al. (1970) . 15 . 3 (20%) . 3
Present series . . 80 . 13 (16%) . 12 1
Total . . . 173 . 28 (16%)
P = Progestins. T = Testosterone.
SPONTANEOUS REGRESSION OF RENAL CARCINOMA
True spontaneous partial or complete regression of cancer is a well-recognised
but rare event. Renal cell carcinoma is one of the principal tumours in which
this phenomenon has been observed, and the obvious question now is whether the
regression of metastases in our hormone-treated cases is the result oftreatment or
due to an unrelated spontaneous event.
From a study of the world literature between 1900 and 1965 and from cases
obtained by personal enquiry Everson and Cole (1966) were only able to collect
176 cases in which they considered there to be adequate evidence of spontaneous
regression of malignant disease. Thirty-one cases had carcinoma of the kidney.
Two of these patients, however, had received hormones (testosterone and predni-
sone) and one, thalidamide. In two further cases the evidence of regression was
based entirely on pathological changes in the primary tumour, one being atrophic
and the other showing necrosis, cyst formation and calcification.
To the 26 cases of clinical regression of untreated renal cancer reported by
Everson and Cole (1966) up to the end of 1965 we can add two further cases
reported during this period and six others published since then, making a total
of 34 examples in the literature up to the end of 1969 (Table VIII). Although
unreported cases have undoubtedly been seen, the incidence of spontaneous
regression in renal cancer seems to be extraordinarily rare.
In a series of 98 cases of renal cancer presenting with metastases and with a
possible follow-up of 12 months reported by Middleton (1967) none showed signs
of spontaneous regression with or without nephrectomy: 91 cases were dead by
1 year and all 98by 2 years. Noexamples ofspontaneous regression were observed
by Riches (1963) in 130 cases of renal carcinoma, by Arner and Von Schreeb
(1966) in 232 cases, and by Rafla (1970) in 244 cases. One remarkable case of
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TABLE VIII.-Renal Adenocarcinoma
Reported cases of spontaneous regression of metastases
Source Cases
Everson and Cole (1966) 26
Gonick and Jackiw (1964) 1
Andrews (1965) . 1
Mims et al. (1966) . 1
Hudgins and Collins (1966) 1
Adolfsson (1966) . 2
Markewitz et al. (1967) 1
Robinson (1969) . 1
Total 34
spontaneous regression ofskeletal metastases following nephrectomyisreportedby
Mims et al. (1966) in their series of 97 cases of advanced renal cancer of which 57
presented with distant metastases.
In a personal series of almost 200 patients with renal cancer referred for
radiotherapy or hormone treatment over the past 10 years, I have seen two cases
in whom spontaneous disappearance of pulmonary metastases occurred. In one
unimpressive case, a woman of 70, brief spontaneous regression of pulmonary
deposits occurred over 3 months and during this time mediastinal nodes increased
and vaginal metastases appeared (Bloom, 1967). Events in the second case were
far more striking.
Case F.B., male aged 55
Nephrectomy for renal carcinoma in presence of bilateral pulmonary metastases. At
operation renal tumour involved peritoneum. In keeping with a " wait and see " policy
Provera treatment not undertaken at this stage. Two months after operation metastases
in left lung smaller; by 5 months all metastases showed signs of regression, and by 7 months
all but one had disappeared. Lungs became clear 10 months after nephrectomy. Patient
remains in excellent health with clear chest more than 2 years after operation (Bloom and
Riddle 1971, not yet published).
In all but two of 36 cases ofspontaneous regression (34 in Table VIII plus two
mentioned here) improvement was confined to pulmonary metastases (Table IX).
Only one example ofspontaneous regression ofskeletal metastases has been found
in the literature (Mims et al., 1966). The other case showing regression of extra-
pulmonary deposits, although accepted by Everson and Cole (1966), seems rather
dubious; residual or recurrent renal carcinoma tissue was said to have been passed
per rectum (Klimpel, 1957).
In the present series of hormone-treated patients clinical evidence of well-
marked tumour regression was observed in the lungs (five cases), in large abdo-
minal tumours (six cases), in the kidney itself (one case) and in the skeleton
(one case) (Table IX). In a further case not included in this table skeletal deposits
remained unchanged for 21 months (case A.D.). It would seem that striking and
prolonged regression of widespread metastases involving the brain, chest and
skeleton, such as occurred in one of our patients (case D.W.), and the virtual
disappearance of a huge abdominal tumour in another (case J.A.D.), have yet to
be reported as a spontaneous event in patients with advanced renal cell carcinoma.
The occurrence of spontaneous regression of renal carcinoma, although a rare
event, naturally calls for caution in the interpretation of the results of hormone
therapy, and emphasises the importance of waiting for clear signs of progressive
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TABLE IX.-Advanced Renal Adenocarcinoma. Site of Regression-
Spontaneous and Treated
Regression
r~~~r
Series Cases Site Cases
Spontaneous . . 36 . Lungs 34
Skeleton 1
? Gut 1
Hormone-treated . 11 . Lungs 5
Abdomen/Scar 6
Skeleton 1
Brain 1
Primary 1
Some overlap of regression sites in hormone-treated cases.
disease before embarking on such treatment. In view of the rarity of spontane-
ous improvement of metastatic renal carcinoma it would appear that definite
regression in 11 cases, continued tumour standstill for 20 months in two others,
and minor or doubtful regressive changes in ten others, in a consecutive series of
80 cases receiving hormone therapy, is more likely to be due to the treatment
than to a natural event. This concept is strongly supported by the short interval
between commencing or changing hormone treatment and observing clinical or
radiological signs ofimprovement. Furthermore, there are now reports ofsimilar
experience from other centres (Melander et al., 1967; Samuels et al., 1968; Talley
et al., 1969; Paine et al., 1970).
Although the phenomenon of spontaneous regression of renal cancer has been
purposely stressed here, the fact remains that once the presence of visceral or
skeletal metastases is established, the disease, in the great majority of untreated
patients, advances and causes death within a year or two.
DISCUSSION AND CONCLUSIONS
The hormonal control of advanced renal cancer, as well as tumours arising in
well-established target organs, such as the breast and endometrium, is temporary
and largely unpredictable as to frequency and duration. Until a lead can be
obtained from further clinical experience or from organ tissue culture and perhaps
biochemical studies, the choice of hormone preparation and dose for a particular
patient with renal cancer must remain largely empirical. Once it is clear that the
disease is advancing and that neither radiotherapy nor surgery are feasible we
have started treatment with Provera, 100 mg. thrice daily by mouth. Ifthere is
no response to this preparation within 8 weeks, or a shorter time if the patient is
rapidly deteriorating, a change has been made to testosterone propionate, 100 mg.
intramuscularly on 5 days per week, later reduced to on 3 days per week. Ifthis
failed we sometimes tried stilboestrol, 15 to 30 mg. daily, or prednisone using
initial doses of 40 mg. daily. Although Samuels et al. (1968) remarked on the
absence of objective responses in cases of renal cancer treated with Proveraby
mouth, tumour regression with this progestin can undoubtedly follow oral as well
as parenteral treatment.
Because a combination of cortisone and Provera produced a more striking
inhibitory effect on the transplantable hamster renal tumour than cortisone alone
(Bloom et al., 1963a), both hormones were tried together in a few patients who
failed to respond to Provera but without success. Significant tumour regression
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was not observed with corticosteroids or with stilboestrol. Brief subjective
improvement was produced occasionally by prednisone.
Although one patient in this series had a remarkable remission lasting 3 years
with testosterone (case D.W.), progestins appear to be generally more effective
than androgens in the treatment of advanced renal cancer. Only one of 15 cases
treated initially with testosterone by Jenkin (1967) showed an objective response.
In two cases of renal carcinoma reported by Talley and his colleagues (1969)
objective responses were not apparent until 5 and 8 months respectively had
elapsed from onset of hormone therapy. It may therefore be advisable to
continue with the initial hormone preparation for longer than the 6 to 8 weeks
which has been our policy in the present series. Perhaps the treatment should not
be interfered with as long as the patient's general condition remains satisfactory
and the metastases stationary.
It must be emphasised that hormone administration is not the treatment of
choice for patients with solitary metastases. Such cases are first considered for
surgical ablation (e.g. lung or brain deposit) or, if this is not feasible, for radio-
therapy (e.g. spinal or multiple brain deposits). Local irradiation offers a quick
and more certain reliefofsymptoms in metastatic renal cancer than does systemic
treatment with hormones or cytotoxic agents.
Prolonged administration of Provera in oral doses of 100 mg. three times daily
is well tolerated and does not appear to be associated with serious side-effects.
Liver and thyroid function tests and glucose tolerance carried out at intervals in
some of our long-term cases remained normal, and there was no fall in plasma
cortisol levels nor in 17-hydroxyketo-steroid excretion. Nevertheless, it is
advisable to continue to watch for endocrine and perhaps hepatic complications.
Macdonald (1970) has reported a reduced adrenal response to metyrapone stimu-
lation tests during treatment with Provera. Stoll et al. (1966) have found raised
serum transaminase levels together with histological evidence of hepatocellular
damage in patients taking the progestin, lynoestrenol, a derivative of 19, nor-
testosterone.
We have recently observed degenerative changes in the wall of the ascending
aorta with vascular rupture in hamsters treated with large doses of megesterol or
melengesterol acetate, compounds with progestational and anti-oestrogenic
activity and structurally closely related to Provera (Cobb et al., 1971). Although
this complication has fortunately not been observed in any of our patients treated
with large doses of Provera, in view of possible changes in the aorta and also the
risk of thrombo-embolic disorders related to the progestational component of
contraceptive pills (Inman et al., 1970), special attention should be given to the
cardiovascular system in advanced cancer cases treated with large doses of proges-
tins that come to autopsy.
Enhanced tumour activity together with marked general deterioration has
been seen in two cases in the present series receiving Provera and one testosterone.
Bergsjo (1965) has reported tumour acceleration in one of 15 patients with endo-
metrial cancer treated with a progestin. Patients receiving hormones for advanced
renal cancer should be watched at frequent intervals during the early stages of
treatment for this complication in which event the preparation should be changed
(e.g. testosterone for Provera, or stilboestrol for testosterone).
Tchao and his colleagues (1968) at this Institute have grown human renal
tumour tissue in organ culture. Attempts are being made to use this technique
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to screen various hormonal preparations against tumour fragments from patients
with carcinoma of the kidney by measuring the inhibition of tritiated thymidine
incorporated into DNA, and the degree ofdegeneration seen in ordinary histological
sections. In this way it is hoped to find the most effective hormonal agent with
which to start treatment in a particular patient. Some ofthe technical difficultics
have now been overcome, but there remains the problem of obtaining a viable
piece of tissue with which to attempt in vitro growth from a tumour which so
often contains necrotic areas.
To date there have been too few tissue culture studies from our cases treated
for metastatic renal cell carcinoma with hormonal agents to permit corrclation
between in vitro and clinical response. More work needs to be done in this
interesting field, especially since hormonal agents, at least in vitro, appear to act
directly on renal tumour cells whilst sparing normal kidney tissue-a potentially
most desirable state of affairs for the chemical treatment of cancer.
The inhibitory effect of hormones on renal carcinoma may be a direct one at
the cellular level and not mediated through the pituitary. This view is supported
by tissue culture studies (Tchao et al., 1968), and also by the absence of signs of
pituitary inhibition (based on thyroid function tests, plasma cortisol levels and
17-hydroxycorticosteroid excretion in the urine) in our patients treated with
Provera. On the other hand, this compound may possess some pituitary inhibi-
tory effect as shown by gonadal atrophy in animals (Ericsson and Dutt, 1965),
a reduced adrenal response to the metyrapone test (Macdonald, 1970) and gonadal
suppression in patients with sexual precocity (Kupperman and Epstein, 1962).
Spontaneous regression does not appear to be the explanation for the well-
marked objective response seen in 13 of 80 hormone-treated cases of advanced
renal cancer in the present series, nor in those reported in the literature. If,
indeed, a natural process and not treatment was responsible for the changes
observed, then its incidence in renal cell cancer must be far greater than at present
generally appreciated. On the contrary, the story of spontaneous regression in
renal cancer favours rather than detracts from the concept ofhormone-dependency
in this disease. The process of spontaneous improvement itself in patients with
renal cancer appears to be sex-related,80% of such cases being males.
On the basis of the present material and the reports in the literature there
seems little doubt that a limited number ofrenal cell carcinomas can be influenced
by hormone therapy, and that this treatment may occasionally offer a new lease
oflife for a limited period oftime to seriously ill patients, even at age 80. Approxi-
mately one in five or six patients appear to derive some benefit from hormone
treatment. In a few other cases the degree of regression is not significant or
clinical improvement is only transitory. Our experience with oral Provera
indicates that striking improvement may occur within 4 weeks of starting treat-
ment and, with continued high doses, last for up to 2 years.
Treatment of cancer with progestational agents is an attractive proposition
since, unlike cytotoxic agents, they are exceptionally free from side-effects.
Patients receiving large doses of Provera, daily over many months or even several
years appear to remain in good health.
I am grateful to Dr. R. G. Jacomb and Dr. W. P. Goodyear of Upjohn Ltd.
for generous supplies of Provera for experimental and clinical work over the past
10 years. My thanks are due to Dr.I. Hamlin for Fig. 4a and 4b.
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